

Announcement

Paiania, 1 December 2023 - Lavipharm S.A. announces, in accordance with Regulation 596/2014/EU, the signing of an asset purchase agreement with Boehringer Ingelheim International GmbH for the acquisition of two analgesic pharmaceutical products, Lonarid N[®] and Lonalgal[®], for the markets of Greece and Cyprus with the intention to commercialize them internationally.

Historical total sales of both pharmaceutical products amounted to approximately €8 mio annually (Wholesale Prices). The transaction will be financed by the company's own funds. The products are commercially available in the Greek market and are expected to be marketed by Lavipharm during the first quarter of 2024 upon completion of the relevant product marketing authorizations' transfer.

###